Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Type 2 diabetes genetics in 125,000 admixed adults from Mexico City.

medRxiv : the preprint server for health sciences·2026
Same author

Upsurge of pneumococcal clade I-α/CC180 serotype 3 and its association with a LytA mutation linked to immune evasion and disease potential: an observational and experimental study.

The Lancet. Microbe·2026
Same author

Metabolomic Profile of Genetic Liability to Type 2 Diabetes Among 125,000 Mexican Adults: A Mendelian Randomization Study.

Diabetes care·2026
Same author

The effect of Indigenous American genomic ancestry on type 2 diabetes in Mexico: an analysis of 134 548 individuals from the Mexico City Prospective Study.

The Lancet. Public health·2026
Same author

Polygenic prediction of coronary heart disease among 130 000 Mexican adults.

European journal of preventive cardiology·2025
Same author

Blood Pressure and Mortality in Mexico City: A Mendelian Randomization Study.

Hypertension (Dallas, Tex. : 1979)·2025

Related Experiment Video

Updated: Jun 25, 2026

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

Thrombophilic polymorphisms in preterm delivery.

Laura L Valdez1, Antonio Quintero, Ernesto Garcia

  • 1Centro de Investigacion Biomedica de Occidente, Instituto Mexicano del Seguro Social, Guadalajara, Mexico.

Blood Cells, Molecules & Diseases
|June 30, 2004
PubMed
Summary
This summary is machine-generated.

Genetic variations in methylenetetrahydrofolate reductase (MTHFR) and angiotensin-converting enzyme (ACE) were linked to premature delivery (PD) in Mexican women. These findings suggest potential genetic markers for identifying women at higher risk for PD.

More Related Videos

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

Modeling Posthemorrhagic Hydrocephalus of Prematurity in Rats
04:12

Modeling Posthemorrhagic Hydrocephalus of Prematurity in Rats

Published on: March 28, 2025

Related Experiment Videos

Last Updated: Jun 25, 2026

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

Modeling Posthemorrhagic Hydrocephalus of Prematurity in Rats
04:12

Modeling Posthemorrhagic Hydrocephalus of Prematurity in Rats

Published on: March 28, 2025

Area of Science:

  • Genetics
  • Obstetrics
  • Molecular Biology

Background:

  • Premature delivery (PD) is a significant global health concern with complex etiology.
  • Genetic factors are increasingly recognized as potential contributors to PD susceptibility.
  • Understanding the genetic basis of PD can inform risk assessment and prevention strategies.

Purpose of the Study:

  • To investigate the association between specific genetic polymorphisms and the risk of premature delivery.
  • To compare the frequency of selected gene variants in women with a history of PD versus a control group.

Main Methods:

  • Genotyping was performed for single nucleotide polymorphisms in tumor necrosis factor (TNF) G-308A, coagulation factors V G1691A and II G20210A, methylenetetrahydrofolate reductase (MTHFR) C677T, and angiotensin-converting enzyme (ACE) insertion/deletion.
  • A case-control study design was employed, comparing 86 women with a history of PD to a control group of at least 162 individuals from Guadalajara, Mexico.

Main Results:

  • A statistically significant increase in the frequency of the methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism was observed in women with a history of PD.
  • The angiotensin-converting enzyme (ACE) deletion polymorphism was also found at a significantly higher frequency in the PD group compared to controls.
  • No significant differences were found for TNF G-308A, coagulation factors V G1691A, or II G20210A polymorphisms.

Conclusions:

  • The MTHFR C677T and ACE deletion polymorphisms may be associated with an increased risk of premature delivery.
  • These genetic variants could serve as potential biomarkers for identifying individuals susceptible to PD.
  • Further research is warranted to elucidate the precise mechanisms underlying these associations.